Insulin resistance both precedes and predicts type 2 diabetesmellitus.1 Although exercise and weight loss ameliorate insulinresistance and may in some cases prevent or delay onset of thedisease,2 therapy that combats insulin resistance in those whofail to change their lifestyle is needed. Current pharmacologicapproaches are unsatisfactory in improving such consequencesof insulin resistance as hyperglycemia, diabetic dyslipidemia,abnormal coagulation and fibrinolysis, and hypertension,3 eachof which may require the use of at least one medication. Thus,the development of drugs targeted to reverse insulin resistanceis important. The insulin-sensitizing thiazolidinediones, whichare selective ligands of the . . . [Full Text of this Article]
The Superfamily of Peroxisome-Proliferator–Activated Receptors
Mechanism of Action of Thiazolidinediones
Insulin Sensitivity and Secretion
Enhancement of Insulin Sensitivity
Indirect Effects in Adipose Tissue
Clinical Efficacy of Thiazolidinediones in Humans
Effects in Patients with Type 2 Diabetes
Hypoglycemic Effects
Effects on Lipids
Effects of Thiazolidinediones on Conditions Characterized by Insulin Resistance
Nonalcoholic Fatty Liver Disease
Polycystic Ovary Syndrome
Lipodystrophies
Effects of Thiazolidinediones on Markers of Cardiovascular Risk
Body Composition and Blood Pressure
Plasma and Urinary Markers
Vascular Function and Disease
Safety and Tolerability of Thiazolidinediones
Weight Gain, Fluid Retention, and Anemia
Hepatotoxicity
Insulin Sensitization beyond Thiazolidinediones
Conclusions
Source Information
From the Division of Diabetes, Department of Medicine, University of Helsinki, Helsinki.
Address reprint requests to Dr. Yki-Järvinen at the Division of Diabetes, Department of Medicine, P.O. Box 340, 00029 HUS Helsinki, Finland, or at ykijarvi@cc.helsinki.fi.
Related Letters:
Thiazolidinediones
Davidson M. B., Edelman S. V., Mascitelli L., Pezzetta F., Yki-Järvinen H.
Extract |
Full Text |
PDF
N Engl J Med 2005;
352:205-207, Jan 13, 2005.
Correspondence
This article has been cited by other articles:
Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., Plutzky, J.
(2008). The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice. J Am Coll Cardiol
0: j.jacc.2008.04.055v1-14006
[Abstract][Full Text]
Monami, M., Lamanna, C., Marchionni, N., Mannucci, E.
(2008). Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials. Diabetes Care
31: 1455-1460
[Abstract][Full Text]
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., Montori, V. M.
(2008). Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials. J. Clin. Endocrinol. Metab.
93: 1135-1142
[Abstract][Full Text]
Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., Strum, J. C., Basu, S., Cheeseman, J., Fielding, B. A., Humphreys, S. M., Danoff, T., Moore, N. R., Murgatroyd, P., O'Rahilly, S., Sutton, P., Willson, T., Hassall, D., Frayn, K. N., Karpe, F.
(2008). Activation of Peroxisome Proliferator-Activated Receptor (PPAR){delta} Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men. Diabetes
57: 332-339
[Abstract][Full Text]
Nakamura, T., Yamamoto, E., Kataoka, K., Yamashita, T., Tokutomi, Y., Dong, Y.-F., Matsuba, S., Ogawa, H., Kim-Mitsuyama, S.
(2008). Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan. Hypertension
51: 296-301
[Abstract][Full Text]
Riddle, M. C.
(2008). Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?: An argument in favor. Diabetes Care
31: S125-S130
[Full Text]
Nilsson, P. M.
(2008). Is Weight Loss Beneficial for Reduction of Morbidity and Mortality?: What is the controversy about?. Diabetes Care
31: S278-S283
[Abstract][Full Text]
Juurinen, L., Kotronen, A., Graner, M., Yki-Jarvinen, H.
(2008). Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses. J. Clin. Endocrinol. Metab.
93: 118-124
[Abstract][Full Text]
Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Corner, A., Bergholm, R., Yki-Jarvinen, H.
(2008). Liver Fat Is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects. Diabetes Care
31: 165-169
[Abstract][Full Text]
Ohnishi, T., Arnold, L. L., Clark, N. M., Wisecarver, J. L., Cohen, S. M.
(2007). Comparison of Endothelial Cell Proliferation in Normal Liver and Adipose Tissue in B6C3F1 Mice, F344 Rats, and Humans. Toxicol Pathol
35: 904-909
[Abstract]
Hardisty, J. F., Elwell, M. R., Ernst, H., Greaves, P., Kolenda-Roberts, H., Malarkey, D. E., Mann, P. C., Tellier, P. A.
(2007). Histopathology Of Hemangiosarcomas in Mice and Hamsters and Liposarcomas/Fibrosarcomas in Rats Associated with PPAR Agonists. Toxicol Pathol
35: 928-941
[Abstract]
Ceolotto, G., Gallo, A., Papparella, I., Franco, L., Murphy, E., Iori, E., Pagnin, E., Fadini, G. P., Albiero, M., Semplicini, A., Avogaro, A.
(2007). Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism. Arterioscler. Thromb. Vasc. Bio.
27: 2627-2633
[Abstract][Full Text]
Kershaw, E. E., Schupp, M., Guan, H.-P., Gardner, N. P., Lazar, M. A., Flier, J. S.
(2007). PPAR{gamma} regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab.
293: E1736-E1745
[Abstract][Full Text]
Murphy, C. E, Rodgers, P. T
(2007). Effects of Thiazolidinediones on Bone Loss and Fracture. The Annals of Pharmacotherapy
41: 2014-2018
[Abstract][Full Text]
Lewanczuk, R., Armstrong, P. W.
(2007). Physiologic Straws in the Wind: In Which Direction Do They Bend?. J Am Coll Cardiol
50: 2059-2060
[Full Text]
Naoumova, R. P., Kindler, H., Leccisotti, L., Mongillo, M., Khan, M. T., Neuwirth, C., Seed, M., Holvoet, P., Betteridge, J., Camici, P. G.
(2007). Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol
50: 2051-2058
[Abstract][Full Text]
Waites, C. R., Dominick, M. A., Sanderson, T. P., Schilling, B. E.
(2007). Nonclinical Safety Evaluation of Muraglitazar, a Novel PPAR{alpha}/{gamma} Agonist. Toxicol Sci
100: 248-258
[Abstract][Full Text]
Dewar, B. J., Gardner, O. S., Chen, C.-S., Earp, H. S., Samet, J. M., Graves, L. M.
(2007). Capacitative Calcium Entry Contributes to the Differential Transactivation of the Epidermal Growth Factor Receptor in Response to Thiazolidinediones. Mol. Pharmacol.
72: 1146-1156
[Abstract][Full Text]
Gustafson, B., Hammarstedt, A., Andersson, C. X., Smith, U.
(2007). Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis. Arterioscler. Thromb. Vasc. Bio.
27: 2276-2283
[Abstract][Full Text]
Westerbacka, J., Kolak, M., Kiviluoto, T., Arkkila, P., Siren, J., Hamsten, A., Fisher, R. M., Yki-Jarvinen, H.
(2007). Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects. Diabetes
56: 2759-2765
[Abstract][Full Text]
Szczepaniak, L. S., Victor, R. G., Orci, L., Unger, R. H.
(2007). Forgotten but Not Gone: The Rediscovery of Fatty Heart, the Most Common Unrecognized Disease in America. Circ. Res.
101: 759-767
[Abstract][Full Text]
Fowler, M. J.
(2007). Diabetes Treatment, Part 2: Oral Agents for Glycemic Management. Clin. Diabetes
25: 131-134
[Full Text]
Lincoff, A. M., Wolski, K., Nicholls, S. J., Nissen, S. E.
(2007). Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA
298: 1180-1188
[Abstract][Full Text]
Lin, J., Zhou, T., Ye, K., Wang, J.
(2007). Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins. Proc. Natl. Acad. Sci. USA
104: 14640-14645
[Abstract][Full Text]
Hasegawa, H., Yamada, Y., Komiyama, K., Hayashi, M., Ishibashi, M., Sunazuka, T., Izuhara, T., Sugahara, K., Tsuruda, K., Masuda, M., Takasu, N., Tsukasaki, K., Tomonaga, M., Kamihira, S.
(2007). A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production. Blood
110: 1664-1674
[Abstract][Full Text]
Perez-Ortiz, J. M., Tranque, P., Burgos, M., Vaquero, C. F., Llopis, J.
(2007). Glitazones Induce Astroglioma Cell Death by Releasing Reactive Oxygen Species from Mitochondria: Modulation of Cytotoxicity by Nitric Oxide. Mol. Pharmacol.
72: 407-417
[Abstract][Full Text]
Tannehill-Gregg, S. H., Sanderson, T. P., Minnema, D., Voelker, R., Ulland, B., Cohen, S. M., Arnold, L. L., Schilling, B. E., Waites, C. R., Dominick, M. A.
(2007). Rodent Carcinogenicity Profile of the Antidiabetic Dual PPAR {alpha} and {gamma} Agonist Muraglitazar. Toxicol Sci
98: 258-270
[Abstract][Full Text]
Zanchi, A., Dulloo, A. G., Perregaux, C., Montani, J.-P., Burnier, M.
(2007). Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am. J. Physiol. Endocrinol. Metab.
293: E91-E95
[Abstract][Full Text]
Arenillas, J. F., Moro, M. A., Davalos, A.
(2007). The Metabolic Syndrome and Stroke: Potential Treatment Approaches. Stroke
38: 2196-2203
[Full Text]
Chou, W.-L., Chuang, L.-M., Chou, C.-C., Wang, A. H.-J., Lawson, J. A., FitzGerald, G. A., Chang, Z.-F.
(2007). Identification of a Novel Prostaglandin Reductase Reveals the Involvement of Prostaglandin E2 Catabolism in Regulation of Peroxisome Proliferator-activated Receptor {gamma} Activation. J. Biol. Chem.
282: 18162-18172
[Abstract][Full Text]
Qatanani, M., Lazar, M. A.
(2007). Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev.
21: 1443-1455
[Abstract][Full Text]
Psaty, B. M., Furberg, C. D.
(2007). Rosiglitazone and Cardiovascular Risk. NEJM
356: 2522-2524
[Full Text]
Pochetti, G., Godio, C., Mitro, N., Caruso, D., Galmozzi, A., Scurati, S., Loiodice, F., Fracchiolla, G., Tortorella, P., Laghezza, A., Lavecchia, A., Novellino, E., Mazza, F., Crestani, M.
(2007). Insights into the Mechanism of Partial Agonism: CRYSTAL STRUCTURES OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma} LIGAND-BINDING DOMAIN IN THE COMPLEX WITH TWO ENANTIOMERIC LIGANDS. J. Biol. Chem.
282: 17314-17324
[Abstract][Full Text]
Ikeda, Y., Takata, H., Inoue, K., Shinahara, M., Inada, S., Maruyama, H., Osaki, F., Suehiro, T., Hashimoto, K.
(2007). Pioglitazone Rapidly Increases Serum Adiponectin Levels in Men With Normal Glucose Tolerance. Diabetes Care
30: e48-e48
[Full Text]
Yaturu, S., Bryant, B., Jain, S. K.
(2007). Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men. Diabetes Care
30: 1574-1576
[Full Text]
Ghosh, S., Patel, N., Rahn, D., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D., Wang, K. X., Swerdlow, R. H.
(2007). The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells. Mol. Pharmacol.
71: 1695-1702
[Abstract][Full Text]
Westerbacka, J.
(2007). PROactive in Patients With Type 2 Diabetes and Previous Myocardial Infarction: Swinging the Sword of Damocles?. J Am Coll Cardiol
49: 1781-1782
[Full Text]
Menzaghi, C., Trischitta, V., Doria, A.
(2007). Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease. Diabetes
56: 1198-1209
[Abstract][Full Text]
Pravenec, M., Kurtz, T. W.
(2007). Molecular Genetics of Experimental Hypertension and the Metabolic Syndrome: From Gene Pathways to New Therapies. Hypertension
49: 941-952
[Abstract][Full Text]
Lindenfeld, J., Masoudi, F. A.
(2007). Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome?. J Am Coll Cardiol
49: 1705-1707
[Full Text]
Goldstein, B. J.
(2007). Clinical Translation of "A Diabetes Outcome Progression Trial": ADOPT Appropriate Combination Oral Therapies in Type 2 Diabetes. J. Clin. Endocrinol. Metab.
92: 1226-1228
[Full Text]
Wajchenberg, B. L.
(2007). {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocr. Rev.
28: 187-218
[Abstract][Full Text]
Wajcberg, E., Sriwijitkamol, A., Musi, N., DeFronzo, R. A., Cersosimo, E.
(2007). Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone. J. Clin. Endocrinol. Metab.
92: 1256-1262
[Abstract][Full Text]
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., Reid, I. R.
(2007). The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. J. Clin. Endocrinol. Metab.
92: 1305-1310
[Abstract][Full Text]
Brunelli, L., Cieslik, K. A., Alcorn, J. L., Vatta, M., Baldini, A.
(2007). Peroxisome Proliferator-Activated Receptor-{delta} Upregulates 14-3-3{epsilon} in Human Endothelial Cells via CCAAT/Enhancer Binding Protein-{beta}. Circ. Res.
100: e59-e71
[Abstract][Full Text]
Kanatani, Y., Usui, I., Ishizuka, K., Bukhari, A., Fujisaka, S., Urakaze, M., Haruta, T., Kishimoto, T., Naka, T., Kobayashi, M.
(2007). Effects of Pioglitazone on Suppressor of Cytokine Signaling 3 Expression: Potential Mechanisms for Its Effects on Insulin Sensitivity and Adiponectin Expression. Diabetes
56: 795-803
[Abstract][Full Text]
Van Vleet, T. R., White, M. R., Sanderson, T. P., Cohen, S. M., Cano, M., Arnold, L. L., Waites, C. R., Schilling, B. E., Mitroka, J., Dominick, M. A.
(2007). Subchronic Urinary Bladder Effects of Muraglitazar in Male Rats. Toxicol Sci
96: 58-71
[Abstract][Full Text]
Ptasinska, A., Wang, S., Zhang, J., Wesley, R. A., Danner, R. L.
(2007). Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway. FASEB J.
21: 950-961
[Abstract][Full Text]
Hiuge, A., Tenenbaum, A., Maeda, N., Benderly, M., Kumada, M., Fisman, E. Z., Tanne, D., Matas, Z., Hibuse, T., Fujita, K., Nishizawa, H., Adler, Y., Motro, M., Kihara, S., Shimomura, I., Behar, S., Funahashi, T.
(2007). Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level. Arterioscler. Thromb. Vasc. Bio.
27: 635-641
[Abstract][Full Text]
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., DeFronzo, R. A.
(2007). Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am. J. Physiol. Endocrinol. Metab.
292: E871-E883
[Abstract][Full Text]
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., Schweizer, A.
(2007). Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial. Diabetes Care
30: 217-223
[Abstract][Full Text]
Kolak, M., Yki-Jarvinen, H., Kannisto, K., Tiikkainen, M., Hamsten, A., Eriksson, P., Fisher, R. M.
(2007). Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab.
92: 720-724
[Abstract][Full Text]
Karim, A., Slater, M., Bradford, D., Schwartz, L., Zhao, Z., Cao, C., Laurent, A.
(2007). Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed-Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug. J Clin Pharmacol
47: 37-47
[Abstract][Full Text]
Rasouli, N., Kern, P. A, Reece, E. A., Elbein, S. C.
(2007). Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.
292: E359-E365
[Abstract][Full Text]
Heine, R J, Diamant, M, Mbanya, J-C, Nathan, D M
(2006). Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?. BMJ
333: 1200-1204
[Full Text]
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., Viberti, G., the ADOPT Study Group,
(2006). Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. NEJM
355: 2427-2443
[Abstract][Full Text]
Dominick, M. A., White, M. R., Sanderson, T. P., van Vleet, T., Cohen, S. M., Arnold, L. E., Cano, M., Tannehill-Gregg, S., Moehlenkamp, J. D., Waites, C. R., Schilling, B. E.
(2006). Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPAR{alpha}/{gamma} Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action. Toxicol Pathol
34: 903-920
[Abstract][Full Text]
Karalliedde, J., Buckingham, R., Starkie, M., Lorand, D., Stewart, M., Viberti, G., for the Rosiglitazone Fluid Retention Study Group,
(2006). Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention. J. Am. Soc. Nephrol.
17: 3482-3490
[Abstract][Full Text]
Kubota, N., Yamauchi, T., Tobe, K., Kadowaki, T.
(2006). Adiponectin-Dependent and -Independent Pathways in Insulin-Sensitizing and Antidiabetic Actions of Thiazolidinediones. Diabetes
55: S32-S38
[Full Text]
YUMUK, V. D
(2006). Targeting Components of the Stress System as Potential Therapies for the Metabolic Syndrome: The Peroxisome-Proliferator-Activated Receptors. Ann. N. Y. Acad. Sci.
1083: 306-318
[Abstract][Full Text]
Chung, S., LaPoint, K., Martinez, K., Kennedy, A., Boysen Sandberg, M., McIntosh, M. K.
(2006). Preadipocytes Mediate Lipopolysaccharide-Induced Inflammation and Insulin Resistance in Primary Cultures of Newly Differentiated Human Adipocytes. Endocrinology
147: 5340-5351
[Abstract][Full Text]
Gilde, A. J., Fruchart, J.-C., Staels, B.
(2006). Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. J Am Coll Cardiol
48: A24-A32
[Abstract][Full Text]
Lu, B., Moser, A. H., Shigenaga, J. K., Feingold, K. R., Grunfeld, C.
(2006). Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. J. Lipid Res.
47: 2179-2190
[Abstract][Full Text]
Imayama, I., Ichiki, T., Inanaga, K., Ohtsubo, H., Fukuyama, K., Ono, H., Hashiguchi, Y., Sunagawa, K.
(2006). Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor {gamma}. Cardiovasc Res
72: 184-190
[Abstract][Full Text]
Watts, N. B., D'Alessio, D. A.
(2006). Type 2 diabetes, thiazolidinediones: bad to the bone?. J. Clin. Endocrinol. Metab.
91: 3276-3278
[Full Text]
van Zwieten, P. A., Mancia, G.
(2006). Background and treatment of metabolic syndrome: a therapeutic challenge.. SEMIN CARDIOTHORAC VASC ANESTH
10: 206-214
[Abstract]
Figaro, M. K., Kritchevsky, S. B., Resnick, H. E., Shorr, R. I., Butler, J., Shintani, A., Penninx, B. W., Simonsick, E. M., Goodpaster, B. H., Newman, A. B., Schwartz, A. V., Harris, T. B., for the Health Aging and Body Composition study,
(2006). Diabetes, Inflammation, and Functional Decline in Older Adults: Findings from the Health, Aging and Body Composition (ABC) study.. Diabetes Care
29: 2039-2045
[Abstract][Full Text]
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., Park, S. W., Lane, N. E., Harris, T. B., Cummings, S. R., for the Health, Aging and Body Composition (Health,
(2006). Thiazolidinedione Use and Bone Loss in Older Diabetic Adults. J. Clin. Endocrinol. Metab.
91: 3349-3354
[Abstract][Full Text]
Hansen, L., Ekstrom, C. T., Tabanera y Palacios, R., Anant, M., Wassermann, K., Reinhardt, R. R.
(2006). The Pro12Ala Variant of the PPARG Gene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-{gamma}/{alpha} Agonist-Induced Edema in Type 2 Diabetic Patients. J. Clin. Endocrinol. Metab.
91: 3446-3450
[Abstract][Full Text]
Bergeron, R., Yao, J., Woods, J. W., Zycband, E. I., Liu, C., Li, Z., Adams, A., Berger, J. P., Zhang, B. B., Moller, D. E., Doebber, T. W.
(2006). Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism. Endocrinology
147: 4252-4262
[Abstract][Full Text]
Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R., Belfiore, A.
(2006). Peroxisomal Proliferator-Activated Receptor-{gamma} Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells. Endocrinology
147: 4463-4475
[Abstract][Full Text]
Svegliati-Baroni, G., Candelaresi, C., Saccomanno, S., Ferretti, G., Bachetti, T., Marzioni, M., De Minicis, S., Nobili, L., Salzano, R., Omenetti, A., Pacetti, D., Sigmund, S., Benedetti, A., Casini, A.
(2006). A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats: Role of Peroxisome Proliferator-Activated Receptor-{alpha} and n-3 Polyunsaturated Fatty Acid Treatment on Liver Injury. Am. J. Pathol.
169: 846-860
[Abstract][Full Text]
Pilch, P. F., Bergenhem, N.
(2006). Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes. Mol. Pharmacol.
70: 779-785
[Abstract][Full Text]
Yokoyama, H., Katakami, N., Yamasaki, Y.
(2006). Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus. Stroke
37: 2420-2427
[Abstract][Full Text]
Gutschi, L M., Malcolm, J. C, Favreau, C. M, Ooi, T. C.
(2006). Paradoxically Decreased HDL-Cholesterol Levels Associated with Rosiglitazone Therapy. The Annals of Pharmacotherapy
40: 1672-1676
[Abstract][Full Text]
Esposito, K., Ciotola, M., Giugliano, D.
(2006). Pioglitazone reduces endothelial microparticles in the metabolic syndrome.. Arterioscler. Thromb. Vasc. Bio.
26: 1926-1926
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., Zinman, B.
(2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
29: 1963-1972
[Full Text]
King, A. B., Wolfe, G., Healy, S.
(2006). Clinical Observations of Exenatide Treatment. Diabetes Care
29: 1984-1984
[Full Text]
Marra, F
(2006). Thiazolidinediones and hepatic fibrosis: don't wait too long. Gut
55: 917-919
[Full Text]
Martens, F. M.A.C., Rabelink, T. J., op 't Roodt, J., de Koning, E. J.P., Visseren, F. L.J.
(2006). TNF-{alpha} induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-{gamma} agonist pioglitazone. Eur Heart J
27: 1605-1609
[Abstract][Full Text]
Leclercq, I A, Sempoux, C, Starkel, P, Horsmans, Y
(2006). Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut
55: 1020-1029
[Abstract][Full Text]
Pasquali, R., Gambineri, A.
(2006). Insulin-sensitizing agents in polycystic ovary syndrome.. Eur J Endocrinol
154: 763-775
[Abstract][Full Text]
Esposito, K., Ciotola, M., Merante, D., Giugliano, D.
(2006). Rosiglitazone Cools Down Inflammation in the Metabolic Syndrome.. Arterioscler. Thromb. Vasc. Bio.
26: 1413-1414
[Full Text]
Hondares, E., Mora, O., Yubero, P., de la Concepcion, M. R., Iglesias, R., Giralt, M., Villarroya, F.
(2006). Thiazolidinediones and Rexinoids Induce Peroxisome Proliferator-Activated Receptor-Coactivator (PGC)-1{alpha} Gene Transcription: An Autoregulatory Loop Controls PGC-1{alpha} Expression in Adipocytes via Peroxisome Proliferator-Activated Receptor-{gamma} Coactivation. Endocrinology
147: 2829-2838
[Abstract][Full Text]
Nigro, J., Osman, N., Dart, A. M., Little, P. J.
(2006). Insulin Resistance and Atherosclerosis. Endocr. Rev.
27: 242-259
[Abstract][Full Text]
Esposito, K., Ciotola, M., Carleo, D., Schisano, B., Saccomanno, F., Sasso, F. C., Cozzolino, D., Assaloni, R., Merante, D., Ceriello, A., Giugliano, D.
(2006). Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome. Diabetes Care
29: 1071-1076
[Abstract][Full Text]
JUNG, T. W., LEE, J. Y., SHIM, W. S., KANG, E. S., KIM, S. K., AHN, C. W., LEE, H. C., CHA, B. S.
(2006). ROSIGLITAZONE RELIEVES ACUTE ETHANOL-INDUCED HANGOVER IN SPRAGUE-DAWLEY RATS. Alcohol Alcohol
41: 231-235
[Abstract][Full Text]
Rizza, R., Henry, R., Kahn, R.
(2006). Commentary on the Results and Clinical Implications of the PROactive Study. Clin. Diabetes
24: 66-68
[Full Text]
Shen, P., Liu, M. H., Ng, T. Y., Chan, Y. H., Yong, E. L.
(2006). Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro. J. Nutr.
136: 899-905
[Abstract][Full Text]
Murphy, E. J.
(2006). Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism. J ANIM SCI
84: E94-E
[Abstract][Full Text]
Previous
